Mechanisms by which cancer chemotherapeutic drugs induce emesis

Seminars in Oncology

Volumn 19, Issue 6 SUPPL. 15, 1992, Pages 2-13

  Cubeddu, Luigi X ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLOROANILINE; 5 HYDROXYINDOLEACETIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOCLOPRAMIDE; ONDANSETRON; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST; VASOPRESSIN;

ANIMAL MODEL; AREA POSTREMA; CANCER CHEMOTHERAPY; CAT; CONFERENCE PAPER; DEAFFERENTATION; DOG; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENTEROCHROMAFFIN CELL; FERRET; GASTROINTESTINAL MUCOSA; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; VOMITING;

ANIMAL; ANTINEOPLASTIC AGENTS; CHEMORECEPTORS; HUMAN; MODELS, BIOLOGICAL; NAUSEA; ONDANSETRON; SEROTONIN; SUPPORT, NON-U.S. GOV'T; VOMITING;

EID: 0027078370     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Emesis as a critical problem in chemotherapy
2. The management of chemotherapy-induced nausea and vomiting
3. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation
4. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and emesis
5. Curso espontaneo se la emesis inducida por cisplatino y evaluacion preliminar de la metoclopramida en dosis bajas intravenosas
6. The role of serotonin in chemotherapy-induced emesis in cancer patients
7. The course of nausea and vomiting after high-dose cyclophosphamide
8. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens
9. Incidence, course and severity of delayed nausea and vomiting following the administration of high-dose cisplatin
10. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin induced nausea and emesis
11. Physiology and pharmacology of vomiting
12. Role of the area postrema in vomiting and related functions
13. Neuropharmacology of chemotherapy-induced emesis
14. The physiology and pharmacology of emesis
15. Discrete lesions of the area postrema abolish radiation-induced emesis in the dog
16. Do humoral factors mediate chemotherapy-induced emesis?
17. Neuropharmacology of emesis induced by anti-cancer therapy
18. Neuropharmacology of emesis induced by cytotoxic drugs and radiation
19. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret
20. Responses of neurons of the canine area postrema to neurotransmitters and peptides
21. Emesis, a species specific stimulus for vasopressin release
22. Influence of the emetic reflex on vasopressin release in man
23. Elevation of plasma antidiuretic hormone (ADH) associated with chemotherapy-induced emesis in man
24. Role of angiotensin-II and vasopressin in cisplatin-induced emesis
25. Differential release of vasopressin and oxytocin in response to abdominal vagal afferent stimulation or apomorphine in the ferret
26. 3 receptors and cytotoxic drug-induced vomiting
27. 3 receptors inhibitors
28. 3-receptor antagonist, GR38032F
29. Antagonism by para-chlorophenylalanine of cisplatin-induced emesis
30. 3 receptors
31. Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs
32. Cisplatin induced emesis: Preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine
33. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret
34. 3 ligand, 3H-GR65630, to the area postrema, vagus nerve and the brains of several species
35. Distribution of 5-hydroxytryptamine (serotonin, enteramine) in the wall of the digestive tract
36. Il sistema cellulare enterocromaffine e l'enteramina (5-idrossitriptamina)
37. Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat
38. Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract
39. Distribution of serotonin (5-hydroxytryptamine) in the human gastrointestinal tract
40. Urinary excretion of 5-hydroxyindoleacetic acid after removal of the large intestine in man
41. The carcinoid syndrome: A treatable malignant disease
42. Efecto dela dieta baja en triptofano sobre la excrecion urinaria de 5-hidroxiindolacetico (5-HIAA) en voluntarios sanos
43. Buspirone blocks motion sickness and xylazine-induced emesis in the cat
44. 8-OH-DPAT suppress vomiting in the cat elicited by motion, cisplatin or xylazine
45. Blockade of 5-hydroxytryptamine3 receptors prevents cisplatin-induced but not motion or xylazine-induced emesis in the cat
46. RU 24969-induced emesis in the cat: 5-HT1 sites other than 5-HT1A, 5-HT1B or 5-HT1C implicated
47. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret
48. 5-HT receptor in the central nervous system, positively coupled with adenylate cyclase, is antagonized by ICS 205930
49. Single-dose ondansetron for the prevention of cisplatin-induced emesis: Efficacy results
50. Delayed emesis after cisplatin treatment: Incidence, source and management